HOW TO USE: Read the Patient Information
Imiquimod (Topical Route) Drug information provided by: Merative, Micromedex
[ 10] The Food and Drug Immune Cell Activation In Autoimmune Disease
In the UK, two strengths of imiquimod cream are available, a 5% cream (trade name cancerous and cancerous lesions such as Bowen’s disease, actinic porokeratosis, lentigo maligna, cutaneous T-cell lymphoma, vulval A very serious allergic reaction to this drug is rare
Mathews MD, Joan L
However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists
When administered orally or topically, it stimulates rapid synthesis and release of cytokines, particularly IFN-α, IFN-γ and interleukin-12, from monocytes, macrophages, dendritic cells and keratinocytes, via activation of Toll-like
Imiquimod is an immune-stimulatory agent agonist of the toll-like receptor 7 that activates the innate and acquired immune response
Imiquimod was employed to induce catagen stage
They may cause a variety of symptoms including pain, tiredness (fatigue), rashes, nausea, headaches, dizziness and more
Preclinical and clinical trials are proposed
Very rarely, a patient can be allergic to Imiquimod cream and develop a severe allergic skin rash
Introduction
Allow the medicine to stay on the treated skin for 8 hours (for actinic keratosis or basal cell carcinoma) or 6 to 10 hours (for genital warts)